Article
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.
Nature communications - 29 Jul 2026
Yousefian Schayan, Schubert Maria-Luisa, Minafra Anna Rita, Derigs Patrick, Gräßle Sarah, Horne Arik, Demel Uta M, Liebaert Julian, Röthemeier Caroline, Pupp Franziska, Höpken Uta E, Krönke Jan, Busse Antonia, Keller Ulrich, Schmitt Anita, Hübschmann Daniel, Müller-Tidow Carsten, Dreger Peter, Schmitt Michael, Haas Simon
Abstract excerpt
Chimeric antigen receptor (CAR) T-cell therapies are typically administered at high doses to maximize durable clinical responses. However, manufacturing constraints can limit the production of sufficient cells to achieve the intended dose. Although some patients experience durable responses after receiving lower CAR-T cell doses, the mechanisms underlying efficacy at these limited cell numbers remain poorly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.